In a groundbreaking development in gene therapy, a baby boy named KJ has become the first recipient of a custom CRISPR treatment designed specifically to address his unique genetic condition. KJ suffers from a severe deficiency in a liver enzyme called CPS1, which can lead to dangerous levels of ammonia in the blood and significant neurological damage. The treatment was administered at the Children’s Hospital of Philadelphia, where researchers Rebecca Ahrens-Nicklas and Kiran Musunuru have been at the forefront of this innovative approach.
This personalized therapy represents a significant advancement in medical science, as it is tailored to correct a specific disease-causing mutation found in KJ’s DNA. Following the infusion, early indications suggest that KJ is experiencing some benefits, although it remains too early to assess the long-term efficacy of the treatment fully.
The rapid approval of KJ's treatment by the FDA was facilitated by the urgent nature of his condition, with the regulatory body recognizing the need for an expedited process. KJ received a low dose of the gene-editing therapy in February 2025, followed by larger doses in subsequent months. As a result, he has shown an ability to consume more protein while reducing his reliance on other medications.
Looking ahead, researchers are optimistic that advancements in personalized gene editing could lead to more effective treatments for a variety of rare genetic disorders. This platform approach, which allows for broader regulatory approval across different mutations, could significantly enhance the feasibility of developing treatments for many patients in the future. However, the costs associated with personalized therapies remain uncertain, although experts believe that advancements may lead to reduced prices over time.